Skip to main content
SpringerLink
Log in

Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

  • Letter to the Editor
  • Published:
Drugs Aims and scope Submit manuscript

A Systematic Review to this article was published on 19 November 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Bonnet U, McAnally H, Scherbaum N. Comment on 'abuse and misuse of pregabalin adn gabapentin: a systematic review update.' Drugs. 2021;2021:5. https://doi.org/10.1007/s40265-021-01494-1.

    Article  Google Scholar 

  2. Bonnet U, Richter EL, Isbruch K, Scherbaum N. On the addictive power of gabapentinoids: a mini-review. PsychiatrDanub. 2018;30(2):142–9.

    CAS  Google Scholar 

  3. Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. EurNeuropsychopharmacol. 2017;27(12):1185–215.

    Article  CAS  Google Scholar 

  4. Bonnet U, Strasser JC, Scherbaum N. Screening for physical and behavioral dependence on non-opioid analgesics in a German elderly hospital population. Addict Behav. 2019;90:265–71.

    Article  Google Scholar 

  5. Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125–56.

    Article  CAS  Google Scholar 

  6. Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77(4):403–26.

    Article  CAS  Google Scholar 

  7. Lyrica [package insert]. New York: Pfizer, Inc.; 2016.

  8. Lile JA, Wesley MJ, Kelly TH, Hays LR. Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol. BehavPharmacol. 2016;27:215–24.

    CAS  Google Scholar 

  9. Evoy KE, Covvey JR, Peckham AM, Reveles KR. Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. Int J Clin Pharm. 2021. https://doi.org/10.1007/s11096-020-01217-8.

    Article  PubMed  Google Scholar 

  10. Evoy KE, Covvey JR, Peckham AM, Ochs L, Hultgren KE. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: an analysis of the Food and Drug Administration Adverse Events Reporting System (FAERS). Res Social Adm Pharm. 2019;15(8):953–8.

    Article  Google Scholar 

  11. Chiappini S, Schifano F. A decade of gabapentinoid misuse: an analysis of the European medicines agency’s “suspected adverse drug reactions” database. CNS Drugs. 2016;30(7):647–54.

    Article  Google Scholar 

  12. Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig. 2017;37(8):763–73.

    Article  CAS  Google Scholar 

  13. Kapil V, Green JL, Le Lait MC, Wood DM, Dargan PI. Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J ClinPharmacol. 2014;78(1):190–1.

    CAS  Google Scholar 

  14. Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse: results of a population-based cohort study in France. Br J ClinPharmacol. 2019;85(6):1260–9.

    CAS  Google Scholar 

  15. Carrasco M, Rao SC, Bearer CF, Sundararajan S. Neonatal gabapentin withdrawal syndrome. Pediatr Neurol. 2015;53(5):445–7.

    Article  Google Scholar 

  16. Huybrechts KF, Bateman BT, Desai RJ, et al. Risk of neonatal drug withdrawal after intrauterine co-exposure to opioids and psychotropic medications: cohort study. BMJ. 2017;358:j3326.

    Article  Google Scholar 

  17. Loudin S, Murray S, Prunty L, Davies T, Evans J, Werthammer J. An atypical withdrawal syndrome in neonates prenatally exposed to gabapentin and opioids. J Pediatr. 2017;181:286–8.

    Article  CAS  Google Scholar 

  18. Peckham AM, Fairman KA, Sclar DA. All-cause and drug-related medical events associated with overuse of gabapentin and/or opioid medications: a retrospective cohort analysis of a commercially insured US population. Drug Saf. 2018;41(2):213–28.

    Article  CAS  Google Scholar 

  19. Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14(10):e1002396.

    Article  Google Scholar 

  20. Macleod J, Steer C, Tilling K, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019;16(11):e1002965.

    Article  Google Scholar 

  21. Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment: a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64.

    Article  CAS  Google Scholar 

  22. Gomes T, Greaves S, van den Brink W, et al. Pregabalin and the risk for opioid-related death: a nested case-control study. Ann Intern Med. 2018;169(10):732–4.

    Article  Google Scholar 

  23. US FDA. FDA in brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. 2019. https://www.fda.gov/news-events/fda-brief/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression. Accessed 2 Nov 2021.

  24. US FDA. FDA warns about serious breathing problems with seizure and nerve pain medications gabapentin (Neurontin, Gralise, Horizant) and pregabalin (Lyrica, Lyrica CR). 2019. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-serious-breathing-problems-seizure-and-nerve-pain-medicines-gabapentin-neurontin. Accessed 2 Nov 2021.

  25. Bonnet U, Specka M, Soyka M, et al. Ranking the harm of psychoactive drugs including prescription analgesics to users and others—a perspective of German addiction medicine experts. Front Psychiatry. 2020;11:592199.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, The University of Texas at Austin, 7703 Floyd Curl Dr., MC 6220, San Antonio, TX, 78229, USA

    Kirk E. Evoy, Sarvnaz Sadrameli & Jillian Contreras

  2. University Health System, San Antonio, TX, USA

    Kirk E. Evoy, Sarvnaz Sadrameli & Jillian Contreras

  3. The University of Texas Health San Antonio School of Medicine, 7703 Floyd Curl Dr., MC 6220, San Antonio, TX, 78229, USA

    Kirk E. Evoy

  4. School of Pharmacy, Duquesne University, 600 Forbes Avenue, 418D Mellon Hall, Pittsburgh, PA, 15282, USA

    Jordan R. Covvey

  5. Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA

    Alyssa M. Peckham

  6. University of Illinois at Chicago, 833 South Wood St., Chicago, IL, 60612, USA

    Sarvnaz Sadrameli

  7. School of Pharmacy, Northeastern University, 140 The Fenway, Boston, MA, 02115, USA

    Alyssa M. Peckham

Authors
  1. Kirk E. Evoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarvnaz Sadrameli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jillian Contreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jordan R. Covvey
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alyssa M. Peckham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kirk E. Evoy.

Ethics declarations

Funding

The authors did not receive funding to complete their study.

Conflict of interest

Alyssa M. Peckham previously served on an advisory board for Alkermes, Inc. Kirk E. Evoy, Sarvnaz Sadrameli, Jillian Contreras, and Jordan R. Covvey have no conflicts of interest to disclose.

Ethics Approval

Not applicable.

Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Availability of Data and Material

Not applicable.

Code Availability

Not applicable.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Evoy, K.E., Sadrameli, S., Contreras, J. et al. Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”. Drugs 81, 615–617 (2021). https://doi.org/10.1007/s40265-021-01495-0

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-021-01495-0

Search

Navigation